Masaki Ishida

6PUBLICATIONS
31CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Jul 23, 2024
Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.

Yohei Matsui, Tadaaki Yamada, Yuki Katayama

|Mar 07, 2024
Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.

Masaki Ishida, Masahiro Iwasaku, Toshifumi Doi

|Oct 06, 2023
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.

Soichi Hirai, Tadaaki Yamada, Yuki Katayama

|Mar 03, 2023
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.

Tae Hata, Chikara Sakaguchi, Keita Hirano

|Nov 18, 2021
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.

Masaki Ishida, Kenji Morimoto, Tadaaki Yamada

Pageof 1

Frequent Collaborators

6 joint publications

Tadaaki Yamada

3 joint publications

Kenji Morimoto

3 joint publications

Takayuki Takeda

3 joint publications

Soichi Hirai